Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.50 |
| ▸ | MAOA | P21397 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765479 | 0.91 | SLC6A4 (0.56) | FABP4FABP5SIGMAR1HDAC1HDAC6 | |
| SCHEMBL15423267 | 0.86 | SIGMAR1 (0.55) | FABP4FABP5SIGMAR1GRIN1GRIN2A | |
| SCHEMBL24701467 | 0.83 | SIGMAR1 (0.53) | FABP4FABP5SIGMAR1GRIN1GRIN2A | |
| SCHEMBL4552481 | 0.81 | FABP4 (0.68) | FABP4FABP5GRIN1GRIN2AGRIN2B | |
| SCHEMBL20763507 | 0.79 | SIGMAR1 (0.53) | FABP4FABP5SIGMAR1GRIN1GRIN2A | |
| SCHEMBL5181736 | 0.79 | MAOA (0.69) | FABP4FABP5GRIN1GRIN2AGRIN2B | |
| SCHEMBL5658338 | 0.79 | MAOA (0.69) | FABP4FABP5GRIN1GRIN2AGRIN2B | |
| SCHEMBL10063551 | 0.79 | MAOA (0.69) | FABP4FABP5GRIN1GRIN2AGRIN2B | |
| SCHEMBL6338101 | 0.79 | MAOA (0.69) | FABP4FABP5GRIN1GRIN2AGRIN2B | |
| SCHEMBL765767 | 0.77 | FABP4 (0.52) | FABP4FABP5SIGMAR1GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2325169-A9 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | University Of Virginia Patent Foundation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2325169-A2 | Lisofylline analogues and their pharmeacuetical uses | University Of Virginia Patent Foundation (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| WO-2007027719-A2 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | FABP4 4237/4885FABP5 404/4885SIGMAR1 1772/4885 |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | FABP4 4237/4885FABP5 404/4885SIGMAR1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.